Synergistic Effects of Melittin and Plasma Treatment:A Promising Approach for Cancer Therapy by Shaw, Priyanka et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.3390/cancers11081109
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Shaw, P., Kumar, N., Hammerschmid, D., Privat-maldonado, A., Dewilde, S., & Bogaerts, A. (2019). Synergistic
Effects of Melittin and Plasma Treatment: A Promising Approach for Cancer Therapy. Cancers, 11(8), 1-19.
[1109]. https://doi.org/10.3390/cancers11081109
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 29. Apr. 2020
cancers
Article
Synergistic Effects of Melittin and Plasma Treatment:
A Promising Approach for Cancer Therapy
Priyanka Shaw 1 , Naresh Kumar 1,*, Dietmar Hammerschmid 2 ,
Angela Privat-Maldonado 1 , Sylvia Dewilde 2 and Annemie Bogaerts 1,*
1 Research Group PLASMANT, Department of Chemistry, University of Antwerp,
BE-2610 Wilrijk-Antwerp, Belgium
2 Laboratory of Protein Science, Proteomics & Epigenetic Signaling, Department of Biomedical Sciences,
University of Antwerp, BE-2610 Wilrijk-Antwerp, Belgium
* Correspondence: naresh.kumar@uantwerpen.be (N.K.); annemie.bogaerts@uantwerpen.be (A.B.)
Received: 18 June 2019; Accepted: 1 August 2019; Published: 3 August 2019


Abstract: Melittin (MEL), a small peptide component of bee venom, has been reported to exhibit
anti-cancer effects in vitro and in vivo. However, its clinical applicability is disputed because of its
non-specific cytotoxicity and haemolytic activity in high treatment doses. Plasma-treated phosphate
buffered saline solution (PT-PBS), a solution rich in reactive oxygen and nitrogen species (RONS) can
disrupt the cell membrane integrity and induce cancer cell death through oxidative stress-mediated
pathways. Thus, PT-PBS could be used in combination with MEL to facilitate its access into cancer
cells and to reduce the required therapeutic dose. The aim of our study is to determine the reduction
of the effective dose of MEL required to eliminate cancer cells by its combination with PT-PBS. For
this purpose, we have optimised the MEL threshold concentration and tested the combined treatment
of MEL and PT-PBS on A375 melanoma and MCF7 breast cancer cells, using in vitro, in ovo and in
silico approaches. We investigated the cytotoxic effect of MEL and PT-PBS alone and in combination
to reveal their synergistic cytological effects. To support the in vitro and in ovo experiments, we
showed by computer simulations that plasma-induced oxidation of the phospholipid bilayer leads to
a decrease of the free energy barrier for translocation of MEL in comparison with the non-oxidized
bilayer, which also suggests a synergistic effect of MEL with plasma induced oxidation. Overall, our
findings suggest that MEL in combination with PT-PBS can be a promising combinational therapy to
circumvent the non-specific toxicity of MEL, which may help for clinical applicability in the future.
Keywords: melittin; reactive oxygen and nitrogen species; oxidation; molecular dynamics; permeation
free energy; cold atmospheric plasma
1. Introduction
Melittin (MEL) is a water-soluble cationic amphipathic 26 amino acid α-helical peptide obtained
from the honeybee (Apis mellifera) venom [1]. It is a very nonspecific cytolytic peptide that rapidly
associates with phospholipid cell membranes. It moves in a lateral direction in the membrane, yielding
oligomerization, thereby leading to structural defects (e.g., pores) in the cell membrane [2]. In addition,
when reaching the intracellular environment, it can act in a similar way on the membrane of internal
organelles, inducing biochemical changes that cause cell death [3,4]. Therefore, several studies have
demonstrated that MEL has inhibitory effects on the proliferation of various cancer cells in vitro via
the induction of apoptosis, necrosis and cell lysis [5]. MEL can target a range of cancer cells, including
those in leukaemia, lung, renal, liver, bladder and prostate cancer, via activation of a caspase-dependent
pathway [6–9]. However, despite the convincing efficacy data against various cancers, its clinical
applicability is precluded due to the non-specific toxicity shown at high doses. Specifically, in vivo
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experiments have demonstrated that MEL can induce cytolysis, aggregation of membrane proteins,
haemolytic activity, spontaneous pain, increased blood flow (neurogenic inflammation) and the
appearance of regions of hyperalgesia around the site of injection [10–13]. These toxic aspects of MEL
are indeed considered as a limiting factor for its use in cancer therapy [14]. Nevertheless, to reduce the
nonspecific toxicity, several combinations of MEL with chemotherapeutic drugs and nanotechnology
have been reported [1,15–17]. However, these combinations still remain challenging [18]. Additionally,
Orsolic and Alonezi et al. explored the dose dependent growth-inhibiting impact of MEL in conjunction
with cytotoxic drugs such as cisplatin and bleomycin on melanoma, HeLa and V79 cells in vitro [19,20].
Further, Alizadehnohi et al. reported that MEL enhanced the cytotoxic impact of cisplatin in human
ovarian cancer cells [21]. However, the combined use of MEL and cisplatin to treat cancer cells still
remained a challenge due to the side effects and off-target toxicity [18,22]. It has been suggested that
the combination of MEL with nanoparticles could increase the safe delivery of significant amounts of
MEL intravenously to target and kill tumours, while reducing the haemolytic activity of MEL [1,15].
However, the role of nanotechnology in delivering MEL is still at its early development stage because
of drawbacks during the preparation for nano delivery systems such as aggregation, morphological
changes, peptide stability, etc. Moreover, these systems are expensive to implement for cancer
therapy [23]. Thus, further studies aiming to reduce the therapeutic dose of MEL and its associated
unspecific cytolytic activity are needed. In this context, we propose the combination of MEL with a
solution treated with cold atmospheric plasma (CAP), a novel therapy that could help to overcome the
current limitations of MEL.
CAP is a partially ionized gas, which contains a mixture of highly reactive chemical species, also
called reactive oxygen and nitrogen species (RONS), such as •OH, O, O2•−, 1O2, O3, NO•, NO2•,
NO2−, NO3− and H2O2 [24,25]. CAP can react with an organic surface without inflicting any thermal
or electrical damage, and recently it has been shown that it can selectively target cancer cells with
minimal effects on normal cells [26]. Thus, CAP is now being investigated and used in various medical
applications, ranging from sterilization, antifungal treatment, tooth bleaching and chronic wound
healing, to cancer therapy [27–29]. Usually it is believed that CAP-produced RONS can enhance the
fluidity of the cell membrane through lipid peroxidation, which eventually affects the intracellular
biochemical signalling pathways [30,31]. In addition, it has been shown that CAP facilitates the uptake
of nanoparticles and enhances their therapeutic action in cells [32]. For instance, it was shown that
gold nanoparticles were endocytosed at an accelerated rate in the U87 cell membrane due to the RONS
generated by CAP [33].
In the present study, we have used in vitro, in ovo and in silico approaches to study the ability of
CAP-treated phosphate buffered saline solution (PT-PBS) to reduce the nonspecific toxicity of MEL and to
induce cell death in A375 melanoma and MCF7 breast cancer cells. To investigate the cytotoxic effect,
various ratios of PT-PBS and MEL alone and in combination were applied to both cell lines. After dose
optimisation of MEL and PT-PBS alone and in combination, we evaluated cell death and lipid peroxidation.
Additionally, to obtain a better insight into the level of synergy of MEL and PT-PBS, we calculated
the free energy barrier for the translocation of MEL across native and (plasma-)oxidised phospholipid
bilayers (PLBs) through molecular dynamics (MD) simulations. In the literature, MD simulations
have reported the interaction of MEL with PLB [34], the peptide orientation [35], the deformation of
lipids [36], and the change in secondary structure [37]. MEL has been shown to maintain a stable
helical structure on the PLB surface [38]. However, only a few articles have reported the simulation of
the free energy of MEL in a native PLB [39,40]. Irudayam et al. [39] studied the free energy barrier for
MEL reorientation from a membrane-bound state (i.e., with the MEL helix parallel to the surface of
the PLB) to a transmembrane state (or T-state, i.e., with the MEL helix perpendicular to the bilayer
surface in the lipid region of the PLB). They found that a higher MEL concentration leads to a decrease
of the free energy barrier. Furthermore, Irudayam and Berkowitz [40] calculated the free energy of
MEL adsorption on the PLB surface. The authors indicated that MEL expresses a strong affinity to
the bilayer surface. Note that the above studies only applied to a native PLB, and not to oxidized
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PLBs, which would be the result of plasma oxidation. Indeed, the translocation of MEL through the
PLB, and the free energy barrier of MEL in an oxidized PLB was not yet investigated. Therefore,
in the present study we analysed the free energy barrier for translocation of MEL in both native and
(plasma-) oxidized membrane. Overall, our experimental and computational approaches reveal that
this combinational therapy opens unique opportunities for future cancer treatment.
2. Materials and Methods
2.1. Reagents and Cell Lines
The following reagents and kits were used in this study: MTT (3-[4,5-dimethylthiazol-2yl]-2,5-
diphenyltetrazolium bromide) (Sigma-Aldrich, Darmstadt, Germany), DMSO (dimethyl sulphoxide)
(Sigma-Aldrich), Annexin V-FITC apoptosis detection kit (BD Biosciences, Allschwil, Switzerland),
Image-iT (Thermo Fisher Scientific, Merelbeke, Belgium), ProLong™ Gold Antifade Mountant with
DAPI (Thermo Fisher Scientific), MDA Assay Kit (CELL BIOLABS, INC, San Diego, CA, USA). Melittin
85% (HPLC) was purchased from Sigma-Aldrich. The human breast adenocarcinoma (MCF7) and
human malignant melanoma (A375) were obtained from the American Type Culture Collection (ATCC,
Manassas, VA, USA).
2.2. Plasma Device and Sample Preparation
MEL 85% (HPLC) was purified from bee venom and reconstituted in sterile PBS to form a stock
solution of 1 mg/mL before storage at −20 ◦C until required. The concentration of MEL mentioned in
the following text (0–10 µL/mL) means that 0–10 µL of the original stock solution were added to cells
contained in 1 mL culture media. In this study, the abbreviations MEL-10, MEL-5, MEL-2.5, MEL-1.2,
and MEL-0.6 are used for the MEL concentrations of 10 µg/mL, 5 µg/mL, 2.5 µg/mL, 1.2 µg/mL, and
0.6 µg/mL, respectively. To make a plasma-treated PBS (PT-PBS) solution, the kINPen® IND plasma jet
(INP Greifswald/neoplas tools GmbH, Greifswald, Germany) was used, as shown in Figure 1.
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Detailed information about the design and operation of the kINPen® IND plasma device was
reported previously [41,42]. Briefly, the kINPen® IND plasma device houses two electrodes: a pin
electrode (1 mm diameter) in the centre that is separated by a dielectric capillary (1.6 mm inner
diameter) from a grounded ring electrode. The plasma is generated by high frequency sinusoidal
voltage of around 2–6 kVpp to the central electrode, with a frequency between 1.0 and 1.1 Hz and
a maximum power of 3.5 W. To control the temperature, the device operates in switch off/on mode
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with a frequency of 2.5 kHz. The plasma is ignited inside the capillary and due to the gas flow it
creates a plasma effluent towards the open side of the device, with a length of 9–12 mm and ca. 1 mm
diameter [41,42]. For the plasma treatments, the plasma source was fed by argon gas for 9 min to treat
2 mL PBS (pH 7.3) in a 12-well plate. During the plasma treatment we kept a 10 mm distance between
the nozzle of the plasma jet device and the liquid surface, as shown in Figure 1 [24,42]. The RONS
present in plasma-treated PBS have been previously described [24], being H2O2 and NO2− as two of
the main RONS responsible of the biological effects of PT-PBS.
2.3. Analysis of Cell Cytotoxicity
The cytotoxicity of PT-PBS and MEL on breast adenocarcinoma (MCF7) and human malignant
melanoma (A375) was evaluated. Both cell lines were cultured in Dulbecco’s Modified Eagle Medium
(DMEM; Life Technologies, Merelbeke, Belgium) supplemented with 10% (v/v) fetal bovine serum (Life
Technologies) and 1% (v/v) penicillin and streptomycin (Life Technologies). The cell cultures were
maintained at a temperature of 37 ◦C in a humidified incubator containing 5% (v/v) CO2. The cells were
grown in 75 cm2 tissue culture flasks until they reached confluence and then they were sub-cultured
for the experiments. Seeded into 24-well plates to grow in complete media were 2 × 105 cells/wells.
After 24 h for the single treatment with PT-PBS and MEL, the medium was removed and immediately
replaced with media supplemented with different percentages of PT-PBS, i.e., 20%, 10%, 5%, 2.5%
and 1.2%, and different concentrations of MEL, i.e., MEL-10, MEL-5, MEL-2.5, MEL-1.2, and MEL-0.6
(as described above). Subsequently, to obtain the synergetic effect of both treatments, the optimized
doses of the single treatments (PT-PBS and MEL) were combined. A total volume of 1000 µL per well
was maintained after addition of the respective percentages of PT-PBS and MEL. In this study, the
abbreviations PT-PBS 20, PT-PBS 10, PT-PBS 5, PT-PBS 2.5 and PT-PBS 1.2 were used for the percentages
of 20%, 10%, 5%, 2.5% and 1.2% of PT-PBS (formed after 9 min plasma treatment), respectively. The
cells were placed in an incubator and their viability was monitored for 24 h post PT-PBS and MEL
treatment. To check the viability, the MTT assay was performed after 24 h. In this assay, 50 µL MTT
(3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide) solution (5 mg/mL in PBS) was added
to each well. After 3 h incubation, the purple formazan precipitates in each well were released in the
presence of 1000 µL DMSO (dimethyl sulphoxide). The absorbance was measured using a microplate
reader (BIO-RAD iMark Microplate reader, Temse, Brussel, Belgium) at 540 nm and the cell viability
was assessed as the absorbance ratio between the treated and control sample, which was directly
proportional to the number of metabolically active cells. To detect cell death, we used the Annexin
V-FITC apoptosis detection kit. The treated/untreated cells were washed with 1 mL of cold 1× binding
buffer after 3 h incubation and were subsequently trypsinized. Annexin V-FITC (0.5 mg/mL) was
added to each sample. After incubation for 15 min at room temperature, the cells were again washed
with PBS, stained with 0.3 mg/mL of PI (Propidium Iodide) and analysed using flow cytometry (Attune
NxT Flow Cytometer, Brussels, Belgium).
2.4. Estimation of Lipid Peroxidation
After standardisation of the optimal dosages of PT-PBS, MEL alone and in combination through
the MTT and flow cytometry analysis, we investigated the peroxidation of membrane lipids by
fluorescence microscopy. We seeded 105 cells on cover glass. After 24 h incubation, the cells were
exposed to PT-PBS, MEL alone or to the combination of PT-PBS 10 and MEL-1.5. After treatment for
3h, the cells were incubated with 10 µM Image-iT (lipid peroxidation) molecular probe for 30 min
and fixed in 4% paraformaldehyde (in PBS) for 20 min and then permeabilized in cytoskeleton buffer
(pH 6.8, 50 mM NaCl, 150 Mm sucrose, 3 mM MgCl2, 50 mM Trizma-base, 0.5% Triton X-100). After
permeabilization, the cells were washed thrice with PBS and subsequently Gold Antifade DAPI was
used to mount the cells. The cells were imaged with Zeiss AxioImager Z1 microscope (Carl Zeiss,
Göttingen, Germany) equipped with an AxioCam MR ver.3.0 using a 40× objective, using filters for
green fluorescent (GFP), red (Texas Red) and blue fluorescent (DAPI) channels. Next, flow cytometry
Cancers 2019, 11, 1109 5 of 19
was used to quantify the fluorescence intensity, after 3 h incubation with PT-PBS, MEL alone and in
combination, at 37 ◦C in a 5% CO2 atmosphere. The treated/untreated cells were incubated with 10 µM
Image-iT molecular probe for 30 min, and then harvested by trypsinization, washed twice with PBS,
and finally the cells were resuspended in PBS to detect the fluorescence intensity by flow cytometry.
To quantify the fluorescence intensity, we used Texas Red® (590 nm) and FITC (510 nm) emission
filters, and we calculated the ratio of intensity in the Texas Red® channel to the intensity in the FITC
channel. Moreover, for all treatments we also measured the malondialdehyde (MDA) concentration by
the MDA assay kit, following the standard protocol according to the manufacturer’s instructions. This
method is based on the reaction of free MDA (present in the sample) with thiobarbituric acid (TBA) to
generate an MDA-TBA adduct and its quantification is generally used as marker for lipid peroxidation.
2.5. Chicken Chorioallantoic Membrane Assay (CAM Assay)
Four-day old fertilized chicken eggs were incubated in a horizontal position for 1 day at 37.7 ◦C
and 65% humidity in an egg incubator with automatic turning function (Ova-Easy 100, Brinsea,
Veenendaal, The Netherlands). On day 5, the upper pole was disinfected and pierced with a 20G sterile
needle (BD) and sealed with medical tape (Leukosilk S, Covamed Farma BVBA, Marke, Belgium).
The eggs were incubated in vertical position (turning function off) to promote the relocation of the air
cell. On day 7, the egg shell was cut to expose the chicken chorioallantoic membrane (CAM). A 1 × 1
mm filter paper soaked in diethyl ether (Fisher Scientific, Merelbeke, Belgium) was briefly applied
on a vascularized region of the CAM and a sterile silicone ring (ID = 5 mm, OD = 6 mm) was placed.
A pellet of A375 cells (2 × 106 cells per egg) was mixed with 15 µL growth reduced factor Matrigel
(8.6 mg/mL, Corning, Amsterdam, The Netherlands) and loaded into the ring. The eggs were sealed
with Tegaderm (3D) and placed back in the incubator for 4 days. On day 11, the Tegaderm was cut
and a sterile plastic ring (ID = 7 mm, OD = 8.5 mm) was placed around the tumour. One hundred
micro litres of untreated PBS, MEL-1.5 µg in 100 µL PBS, 10% of PT-PBS and its combination (MEL
+ PT-PBS) were loaded into the ring. The eggs were sealed with Tegaderm and incubated until the
end of the experiment. The cytotoxic effect of the treatments was assessed on day 14 when tumours
were excised and weighed in a precision balance (Mettler Toledo, Fisher, Merelbeke, Belgium). All
steps outside the incubator were carried out using a heat block (set at 37.7 ◦C) with a custom-made
egg-shaped aluminium adapter.
2.6. Immunohistochemical Analysis for Ki-67
After weighing, the tumours were fixed with 4% paraformaldehyde for 14 h at 37 ◦C prior to
paraffin embedding. Sections of 5 µm were cut, deparaffinized, rehydrated and stained with 1:1
haematoxylin and 0.5% eosin (HE) solution for histological analysis. For Ki-67 staining, antigen retrieval
was performed with citrate buffer (10 mM, pH 6), at 96 ◦C for 20 min. Sections were permeabilised
in 0.1% Tween-20 and blocked with 3% H2O2 in PBS (10 min, RT) and 2% BSA (30 min, RT). The
primary antibody incubation was 40 min at RT (1/75 dilution; Mouse Anti-Human Ki-67 Antigen,
Clone MIB-1, Agilent, Santa Clara, CA, USA), followed by incubation with the secondary antibody
(30 min at RT; Envision Flex HRP, Agilent, Diegem, Belgium). Diaminobenzidine was used to visualize
positive staining and haematoxylin to counterstain. Sections were imaged with a Zeiss AxioImager Z1
microscope (Carl Zeiss, Göttingen, Germany) equipped with an AxioCam MR ver.3.0.
2.7. Mass Spectrometry Analysis
To detect the conformational change in MEL by native mass spectrometry (MS), 1 mg of MEL
was dissolved either in 1 mL untreated PBS (control) or in 1 mL PT-PBS (i.e., 100% of PT-PBS). Each
sample (50 µL) was buffer exchanged to a MS compatible 100 mM ammonium acetate solution using a
Micro Bio-Spin 6 column (Bio-Rad, Hercules, CA, US). MS experiments were conducted on a Synapt
G2 HDMS (Waters, Manchester, UK) instrument. For this purpose, 3 µL of sample was loaded into an
in-house produced gold-coated borosilicate capillary and mounted onto the instrument. The sample
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was ionized by nano-electrospray ionization (nESI) and the generated ions were drawn into the vacuum
of the instrument. The crucial parameter settings were 1.2 kV capillary voltage, 10 V sampling cone, 1
V extractor cone, 10 V and 2 V collision energy in the trap and transfer cell, respectively. Pressures
throughout the instrument were set to: 2.75 mbar backing pressure, 4.55 × 10−3 mbar in the source
region, and 2.5 × 10−2 mbar in the trap and transfer collision cells.
2.8. Statistical Analysis
Data was analysed using the Students’ t-test comparison analysis. The data was considered
significantly different when * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. All values represent experiments
done in triplicates. Data shown as mean ± standard deviation (SD). Prism (Graphpad Software Inc.,
San Diego, CA, USA) and Excel Software (Microsoft Inc., Redmond, WA, USA) was used to compare
the groups.
2.9. Computational Analysis
2.9.1. Simulation Setup
To support the experiments, we performed MD simulations to study MEL translocation across
native and oxidized PLBs. We chose the PLB as the model system for the cellular membrane, as it
provides the structural framework for the cell membrane. The PLB considered in this study consists of
palmitoyl-oleoyl-phosphatidylcholine (POPC) lipids (see Figure 2).
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To study the effect of plasma-induced oxidation of the phospholipids on the translocation of
MEL through the PLB, we assumed aldehyde oxidation products (POPC-ALD, see Figure 2b), which
are found to be one of the key oxidation products [43]. The si ulations were carried out using the
GROMACS package (version 5.1) [44], applying the R S 54 7 force field [45]. The force field
parameters of the aldehyde product of the oxidized POPC (POPC-ALD) were obtained from [46].
To generate the initial configurations of the intact (or native) and oxidized POPC systems, we applied the
Packmol package [47]. Each system consists of 20,000 water molecules together with 128 phospholipids
organized in two layers (i.e., 64 lipids with corresponding water layer at the top, and 64 at the bottom,
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see Figure 2a). MEL has an α-helical configuration and was placed on the upper side of the PLB, i.e.,
in the water phase at about 1.5 nm above the head group region of the bilayer (see Figure 2a, and
below for more details). To evaluate the effect of plasma-induced oxidation of the native POPC, we
replaced randomly 64 POPC molecules with POPC–ALD (i.e., 32 at the top and 32 at the bottom),
corresponding to 50% oxidation. Thus, we studied two model systems, i.e., native (0% oxidation) and
50% aldehyde-oxidized PLBs. We assumed 50% oxidation, which is enough to clearly investigate the
effect of translocation of MEL across the bilayer, but low enough to avoid pore formation within the
simulation [48]. In order to obtain the average free energy profile (FEP) of MEL translocation across
each system (see section below), we created three model systems for both native and 50% oxidized
PLB. In each system we changed the position of MEL in the xy-plane, keeping the distance between
MEL and the centre-of-mass (COM) of the bilayer constant in the z-direction (reaction coordinate).
Moreover, to neutralize the system, we added 6 Cl− ions, because of the +6 charge of MEL. After
construction of the hydrated membranes with equilibrated MEL at the top, all the systems were
energy-minimized using the steepest descent algorithm. Further, all structures (i.e., three native and
three oxidized PLBs) were equilibrated for 200 ns (for the native case) and 300 ns (for the oxidized
case) in the NPT ensemble (i.e., at constant number of particles, pressure and temperature), at 310 K
and 1 bar, employing the semi-isotropic Parrinello–Rahman barostat [49] with a compressibility and
coupling constant of 4.5 × 10−5 bar−1 and 1 ps, respectively, as well as Nose-Hoover thermostat [50]
with a coupling constant of 0.2 ps. For the non-bonded interactions, a 1.2 nm cut-off was applied.
Periodic boundary conditions were applied to all systems in all Cartesian directions. The long-range
electrostatic interactions were described by the particle mesh Ewald (PME) method [51], using a 1.2 nm
cut-off for the real-space interactions and 0.15 nm spaced-grid for the reciprocal-space interactions. The
SPC/E (extended simple point charge) model was used to represent the water molecules surrounding
the membrane and MEL. In all simulations, we used a time step of 2 fs.
2.9.2. Umbrella Sampling
In order to determine the FEPs of MEL translocation through the native and 50% oxidized PLBs,
we applied umbrella sampling (US) simulations. To avoid disturbances in the hydrophobic part of the
bilayer, we kept MEL perpendicular to the surface (as shown in Figure 2a), also called the transmembrane
state (T state), which is the stable state of MEL when it begins to diffuse inside the membrane [52].
Furthermore, to avoid the formation of the U-shaped conformation of MEL, we pulled the COM of the
first three residues of the N-terminus of MEL towards the bilayer (see arrow indicated in Figure 2a).
For each FEP, we extracted 95 windows along the z-axis, which were separated by 0.1 nm. These
windows were obtained by pulling the COM of the first three residues of the N-terminus of MEL in the
z-direction (as mentioned above), applying a harmonic bias between MEL and the COM of the PLB,
with a force constant of 2000 kJ·mol−1 nm−2 and a very slow pulling rate of 0.001 nm·ps−1. Each US
simulation lasted for 200 ns, and the last 50 ns were used to collect the US histograms and to calculate
the FEPs. A periodic version of the weighted histogram analysis method (WHAM) [53] implemented
in GROMACS, was applied to construct the FEPs. The final energy profiles were obtained by averaging
over three FEPs for each system, which differ from one another based on their starting structure,
to allow for some statistical variations.
3. Results and Discussion
3.1. Effects of PT-PBS and MEL on Cell Viability and Dose Optimization
To verify the effect of MEL, PT-PBS alone and its synergy on the growth of melanoma and breast
cancer cells, we analysed the cell viability using the MTT assay. Treatments by MEL and PT-PBS alone
exerted a concentration-dependent cytotoxic effect on both cell lines (Figure 3a,b). Up to 2.5 µg/mL of
MEL shows significant decrease in viability in both cell lines. In addition, PT-PBS 20 and PT-PBS 10
also show a significant inhibitory effect on both cell lines after incubation for 24 h. For the controls,
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20% and 10% non-treated PBS in the culture media were used for the MTT assay for the A375 and
MCF7 cells, respectively, and 10% non-treated PBS in culture media for the cell death analysis and
lipid peroxidation analysis in both cell lines.
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Figure 3. Estimation f optimal doses of MEL and PT-PBS alone, f r the cy otoxicity of A375 and MCF7
cells. We measur d the cell viability of (a) A375 cells, and (b) MCF7 cells, at different doses of MEL
and PT-PBS, after 24 h incubation. (c) Half maximal inhibitory concentration (IC50) values of MEL and
PT-PBS. Data shown as mean ± SD; * = p ≤ 0.05; ** = p ≤ 0.01; *** = p ≤ 0.001.
The half max mal inhibitory concentrati s (IC50) of MEL and PT-PBS are shown in Figur 3c.
The IC50 values of MEL in A375 and CF7 cells w re 2.5 and 2.8 µg/mL, respectively, while they were
16.4% and 16. %, respectively, for PT-PBS. Based on the IC50 values, we performed the combined
treatment of MEL and PT-PBS, to invest g te the synergy betwe n both. For this purpose, we fixed
concent ation of PT-PBS to a value lower than its IC50 values (i.e., we fixed it at 10%) and we varied the
concentrations of MEL in a range lower than its obtained IC50 values (i.e., 2, 1.5, 1 and 0.5 µg/mL).
As shown in Figure 4a,b, PT-PBS 10 alone yielded 65% viability for both A375 and MCF7 cells,
while MEL-2, MEL-1.5, MEL-1 and MEL-0.5 alone resulted in ca. 50%, 60%, 77% and 90% cell viability
for the A375 cells, and ca. 55%, 70%, 80% and 95% for the MCF7 cells, respectively. However, the
combination of both showed a significant (p < 0.001) decrease, to ca. 8%, 15%, 32% and 60% for the
different MEL concentrations in the A375 cells, and to ca. 10%, 17%, 34% and 64% for the different
concentrations in the MCF7 cells.
To determine the synergistic cytotoxic effect of the combination of PT-PBS and MEL, the
combination index (CI) value was calculated based on [54]. It is generally accepted that CI values < 0.1
indicate very strong synergism, CI = 0.1–0.3 strong synergism, CI = 0.3–0.7 synergism, CI = 0.7–0.9
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slight synergism and CI = 0.9–1.1 nearly additive, while CI = 1.1–1.45 refers to slight to moderate
antagonism [54,55]. As illustrated in Figure 4c, the CI analysis on A375 cells shows a synergistic
cytotoxic activity for the combination of PT-PBS 10 with the following concentrations of MEL-2
(CI = 0.384), MEL-1.5 (CI = 0.412), MEL-1 (CI = 0.812), and MEL-0.5 (CI = 1.012). For the MCF7 cells,
the CI values are very similar, i.e., MEL-2 (CI = 0.372), MEL-1.5 (CI = 0.426), MEL-1 (CI = 0.846), and
MEL-0.5 (CI = 1.02). The combination of PT-PBS 10 with MEL-2 or MEL-1.5 clearly yields synergism,
indicating that this combination can reduce the toxicity dose of MEL, and thus avoid the side effects
related to higher doses of MEL. However, literature shows that MEL concentrations of up to 2 µg/mL
do not significantly inhibit cell viability in melanoma and lung cancer [22,27,56]. Thus, we performed
our further experiments with a low dose, i.e., MEL-1.5, in combination with PT-PBS 10, as the optimal
combination for both cells.
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Figure 4. Analysis of cell viability of (a) A375 and (b) MCF7 cells treated with a fixed dose of PT-PBS
(10%), and varying doses of MEL (i.e., 2, 1.5, 1 and 0.5 µg/mL) a one nd in comb nation, 24 h after
treatment. (c) Comb ation index (CI) of PT-PBS (10%) with MEL (at 2, 1.5, 1 and 0.5 µg/mL), in A375 and
MCF7 cells (see text). All values ar expressed as mean ± SD; * = p ≤ 0.05; ** = p ≤ 0. 1; *** = p ≤ 0.001.
3.2. Influence of PT-PBS and MEL on Cell Death
To further demonstrate the synergism, and for clearer observation of cancer cell death after
treatment with PT-PBS and MEL alone and in combination, we performed flow cytometry analysis.
We also analysed the degree of apoptosis/necrosis after treatment of both cell types. FITC Annexin V
and PI negative cells are considered as viable; if the cells are FITC Annexin V positive and PI negative
that cells are considered as early apoptotic; however, if cells are both FITC Annexin V and PI positive
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that cells are considered as late apoptotic or already dead (by necrosis). Hence, this assay does not
differentiate between apoptotic and necrotic cell death as both populations are positive for both FITC
Annexin V and PI. Therefore, in the current experiments, Annexin V and PI positive staining represent
late apoptotic combined with necrotic cell death [57].
As shown in Figure 5a,c for A375 cells, PT-PBS 10 and MEL-1.5 alone induced 38% and 35%
late apoptosis/necrosis (Annexin V positive, PI positive), respectively, while the combined exposure
induced 96% late apoptosis/necrosis (p ≤ 0.01). In a similar way, PT-PBS 10 and MEL-1.5 alone induced
37% and 30% late apoptosis/necrosis in MCF7 cells, respectively, while their combination induced
92% late apoptosis/necrosis (p ≤ 0.01, Figure 5b,d). These results indicate that the combined action of
PT-PBS 10 and MEL-1.5 on both cancer cell lines is more than the sum of their individual effects, which
is in agreement with the CI values shown above (Figure 4c). Altogether, these findings support the
synergistic cytotoxic action of PT-PBS 10 and MEL-1.5 in cancer cells.
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3.3. Effect of PT-PBS and MEL on Lipid Peroxidation
Lipid peroxidation generally refers to the oxidative degradation of cellular lipids by reactive
oxygen species. Peroxidation of unsaturated lipids affects cell membrane properties [58] and signal
transduction pathways [59]. Thus, to evaluate the change in membrane integrity upon treatment with
PT-PBS and MEL, we estimated the lipid peroxidation with the MDA assay and fluorescent probe.
As shown in Figure 6a, the A375 cells incubated with PT-PBS 10 and MEL-1.5 alone yielded ca.
5.2 µ and 4 µ peroxidation product ( alondialdehyde; MDA), respectively, while in combination
they exhibited a significant formation of MDA (ca. 15 µM, p ≤ 0.01). Likewise, for the MCF7 cells,
PT-PBS 10 and MEL-1.5 alone produced ca. 4.5 µM and ca. 4 µM MDA respectively, while their
combined exposure shows a significantly higher MDA production (ca. 10.5 µM, p ≤ 0.05). In addition,
lipid peroxidation following PT-PBS 10, MEL-1.5 and combined exposure was qua tified in both
cancer cells, using the ratio of green an red fluoresc nce i tensities, as show in Figure 6b. The ratios
increased sig ifica tl i t ll li t e co bined treat ent (p ≤ 0.05).
Figure 6c, fl f t e 375 and MCF7 cells stained with lipid peroxide
detection reagents, after ad ition of PT-PBS 10, MEL-1.5 alone and in combination. Compared with t e
separate treatments, the combined exposure shows most of the signal is in the green cha nel, which
indi ates lipid peroxidation. We also d tected lipid peroxidation products around the membrane,
indicating a change in the phys cal properties of the c llular membranes. This can cause covalent
modification o proteins and nucleic acids, whi h mig t eventually be critical med ators of oxidative
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stress-mediated cell death [59]. Thus, the combined treatment with PT-PBS 10 and MEL-1.5 induces
lipid peroxidation in both cancer cell lines, which correlates with the cytotoxic effect of the combined
treatment observed above.
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3.4. Effect of PT-PBS and EL on alig a t ela o a a cer ors of the - odel
Malignant solid tu o rs r l s r s i ll si i-67 staining. The
stained tumour tissue sections displayed changes in morphol gy upon all treatments. Interestingly, the
combined tr atment induced more cellular shrinking a d presence of pyknotic dark small nuclei as a
re ult of chromatin condensation, compared to th PT-PBS 10 and MEL-1.5 treatments alone (Figure 7a).
In contrast, u treated (control) cells presented a more prominent malignant phenotype with mitotic
act vity (HE staining, Figure 7a). To assess the pr liferative state o cells in the treat d tumours, tissue
sections were stain d for the proliferation marker Ki-67. The untreated tumours presented the highe t
lev ls of Ki-67 positive cells. We observed that tumours exposed to the combined t eatment present d
the lowest number of Ki-67 positive cell , followed by tumours treated with PT-PBS 10 and MEL-1.5
alone (Figure 7b). These results suggest that the combined treatment of MEL+PT-PBS has a detrimental
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effect on cell proliferation, as it reduced the number of Ki-67 positive cells more efficiently than the
sum of the individual treatments.
In agreement with the histological analysis of tumour specimens, the tumour weight also
demonstrated a reduction of tumour size upon treatment (Figure 7c,d). The combined treatment
significantly reduced the tumour weight by approx. 76%, whereas the tumours treated with PT-PBS
10 and MEL-1.5 showed a reduction in weight of approx. 30% and 35%, respectively (Figure 7c).
Hence, these results indicate that the combined treatment induced a synergistic reduction of cell
proliferation, as its effect on tumour weight (76% reduction) was approximately 11% higher than the
sum of both treatments (reductions of 30% + 35%). These findings are in agreement with the in vitro
results shown above.
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3.5. Plasma Oxidation of MEL: Mass Spectrometry Analysis
To better understand the synergistic effect of PT-PBS and MEL, we investigated the effect of plasma
treat ent on the oxidation level of MEL. For this purpose, we dissolved MEL either in untreated
(control) or in PT-PBS buffer and we incubated the solution for 1, 60, or 120 min. Figure 8 shows the
native MS measurements of the control (a) and the plasma-treated (b) samples.
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ionization [60], as indeed reported for MEL [61], but at much harsher operating conditions than 
applied in this experiment. Moreover, the measurements do not show an increase in the number of 
oxidations over time. Thus, no differences were observed in the spectra acquired after one minute 
and after two hours. Independent of whether the oxidations are already present in solution or are 
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Figure 8. Native mass spectrometry (MS) of MEL. The figure shows an overview of native MS spectra
of MEL solubilized either in (a) untreated or (b) plasma-treated PBS buffer after different time points of
incubation (0: 1 min; 1: 60 min; 2: 120 min). The inset in each spectrum displays the m/z region from
700 to 750 (zoom-in of the [M + 4H]4+ species). The satellite peaks highlighted in the insets correspond
to oxidations of MEL.
The indices refer to the different time points of incubation (0: 1 min, 1: 60 min, 2: 120 min).
As illustrated, the comparison between control and plasma treatment reveals no differences in the
oxidation level of MEL. The observed oxidations (700–750 m/z) may originate from the electrospray
ionization [60], as indeed reported for MEL [61], but at much harsher operating conditions than applied in
this experiment. Moreover, the measurements do not show an increase in the number of oxidations over
time. Thus, no differences were observed in the spectra acquired after one minute and after two hours.
Independent of whether the oxidations are already present in solution or are induced by the electrospray
ion source, in any case the plasma treatment applied in the form of solubilizing MEL in plasma-treated
PBS buffer does not have any influence on these observed oxidations. Hence, we can conclude that MEL
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is not oxidized by plasma, and that the synergistic effects of MEL and PT-PBS must be attributed to
other effects. One possibility is the enhanced translocation of MEL through the cell membrane upon
plasma-induced oxidation of the phospholipids. This will be discussed in the next section.
3.6. MEL Translocation across Native and Oxidized Phospholipid Membrane Revealed through
MD Simulations
To gain further insight into the experimentally observed synergetic effect between MEL and the
RONS present in PT-PBS and to investigate the mechanisms of MEL access to cancer cells through
oxidized membranes, we performed US MD simulations. This method allows us to elucidate the MEL
translocation across the native and oxidized PLBs, based on the FEPs plotted in Figure 9.
Based on the polarity of the lipids, the hydrophilic part refers to the upper and lower lipid head
groups (light blue colour in Figure 9a), while the hydrophobic part refers to the lipid tails of the PLB (grey
colour in Figure 9b–e). In the native case, when MEL enters from the water phase to the hydrophilic
head group of the upper leaflet (see Figure 9b,c), it shows a high affinity with the (charged) head groups
of the PLB, due to strong Coulomb interaction [62]. As a result, the potential of mean force for insertion
of MEL shows a drop in the free energy barrier, making insertion of MEL favourable (see first minimum
near z = 1.5–2 nm in Figure 9a, indicated with the arrow). Subsequently, the N-terminal of MEL moves
through the hydrophobic tail region (see Figure 9d,e) and experiences a permeation barrier at the centre
of the bilayer. It is due to the fact that the residues of MEL near the C-terminal (i.e., LYS21, ARG22, LYS23
and ARG24) with a net charge of +4 prefer to stay at the upper head group-water interface, whereas the
N-terminal residue LYS7 with a net charge of +1 prefers to move into the inner head group-tail interface,
which eventually leads to an increase of the free energy barrier at the centre of the PLB [62]. When (the
N-terminal of) MEL traverses further towards the lower leaflet, the free energy drops again, because
most of the hydrophobic residues of MEL stay in the hydrophobic region of the PLB. Finally, at the
lower head group region of the PLB, the energy rises again, because the charged residue LYS7 near the
N-terminal of MEL binds with the head group of the lower leaflet, resulting in a new barrier against
translocation [40]. Moreover, as MEL penetrates through the bilayer, its conformation changes, but most
of its helical structure is retained at the surface of the PLB (see Figure 9b–d).
It is important to notice that the first free energy maximum for the native case (see Figure 9a) is
29.28 ± 1.04 kJ/mol, obtained at the centre of the bilayer (i.e., z = 0 nm) and the second maximum is
24.9 ± 2.3 kJ/mol, obtained at around z = −2 nm, which indicates that MEL has to face multiple barriers
across the bilayer, making the translocation more difficult. In addition, we observed an asymmetric
free energy profile, that is most likely due to the disturbance and conformational changes in the PLB,
which was observed in other simulation studies as well [62].
On the other hand, in the oxidized PLB, the energy reaches a minimum in the centre of the bilayer,
because when the lipid tails are oxidized, they become less apolar and hence the hydrophilicity of the
membrane core increases dramatically, so that MEL can penetrate more easily. In addition, on top of
the general minimum in free energy, there are multiple free energy local maxima and minima, due to
interactions of the amino acid side chains of MEL with the lipid tails.
Previous reports suggest that cancer cells are more susceptible than normal cells to oxidative
damage and cell death induced by CAP treatments [26,63–66]. In silico studies of CAP-induced
oxidation of phospholipids in cell membranes demonstrated that cell membranes with higher fractions
of cholesterol (i.e., normal cells) were protected from pore formation. In contrast, when lower
concentrations of cholesterol were present (i.e., cancer cells), the cell membrane was more vulnerable
to oxidative stress and it favoured pore formation [48]. The pores generated in the cell membrane
facilitated the pass of plasma-generated ROS into the intracellular compartment [67,68], where they
could exert further oxidative damage to cells. Our simulation results are in agreement with the
literature, as we demonstrate here that RONS present in PT-PBS (e.g., H2O2, NO3− and NO2−
ions [24,30] oxidize the cell membrane (as can be deduced from the lipid peroxidation experiments, see
Figure 6). In addition, from Figure 9a we conclude that the free energy barrier for the transport of
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MEL across the PLB decreases upon oxidation, and even disappears in large enough oxidation degrees.
Hence, the probability of MEL permeation to the cell interior increases, so that lower doses of MEL
already give cytotoxic effects. As cancer cells are more sensitive to oxidative stress than normal cells
due to the high levels of steady-state RONS produced [69], anticancer treatments (such as the one
described here) that increase the oxidative stress levels beyond the RONS threshold could aid to the
elimination of cancer cells without damaging the normal cells [70]. Altogether, our results indicate that
the effectivity of the combined treatment to eliminate cancer cells relies on the ability of both MEL and
PT-PBS to: (i) disrupt the fluidity and integrity of the cell membrane; (ii) facilitate their access into
the intracellular compartment; (iii) damage the intracellular components of cancer cells to induce cell
death. Due to the differences in the lipid composition of cell membranes [48] and steady-state ROS
levels produced by normal and cancer cells, normal cells are expected to be less susceptible to the lipid
peroxidation and pore formation induced by the combined treatment. An insufficient damage to the
cell membrane integrity of normal cells would mean a reduction in the access of PT-PBS and MEL into
the cell, thus limiting their cytotoxic effects. Further studies are required to ensure the safety of the
combination of MEL and PT-PBS for the future treatment of cancer patients.
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(b–e) MEL at different positions of the native PLB. P and N atoms in the PLB are shown in red and green,
respectively. MEL (shown within dashed circles/ovals) and the lipid tails are presented in magenta and
grey, respectively. The light blue colour in (a) represents the upper (right) and lower (left) head groups
of the PLB. The yellow arrows in (a,b) indicate the direction of MEL translocation. At the bottom of
(b–e), the respective positions of the N-terminal of MEL are indicated, referring to the x-axis of (a).
4. Conclusions
Bee venom is considered as a potential weapon against cancer. MEL, a major polypeptide of
bee venom, is thought to function as lytic agent, and has been used traditionally in various cancer
therapies [2]. However, at high treatment doses, it exhibits severe nonspecific toxicity, because of
its lytic properties [3]. In this paper, we describe for the first time a combined treatment of MEL
with plasma-treated PBS that reduces the effective dose of MEL required to eliminate cancer cells.
We have used in vitro, in ovo and in silico approaches to investigate the synergistic effect of PT-PBS
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and MEL on A375 melanoma and MCF7 breast cancer cells. We have previously demonstrated that
CAP-treated liquids such as PBS, deionized water and culture media, can effectively eliminate pancreatic
cancer, melanoma and glioblastoma cancer cells [24,42,71]. In these studies, H2O2 and NO2− present in
CAP-treated liquids play a key role in the induction of cell death in cancer cells. These RONS can further
favour the formation of ONOO− [24,42,63], which has a high potential to induce lipid peroxidation [72].
Our findings suggest that the ability of the RONS present in PT-PBS to damage the lipids in the cell
membrane increases the MEL permeation and therefore lowers the therapeutic dose of MEL required to
exert a cytotoxic effect in cancer cells. Our study demonstrates the synergistic effect of MEL and PT-PBS,
i.e., the combined cancer cell cytotoxicity for both A375, MCF7 cell lines and malignant melanoma
cancer tumours is larger than the sum of both individual effects of MEL and PT-PBS at the same
concentration. This is supported by the calculated combination index (CI) values of 0.4, which indicates
synergism. This synergy is attributed to the change in membrane integrity upon peroxidation of the
membrane lipids by the RONS present in PT-PBS. As a result of the change in membrane integrity, the
MEL translocation rate through the cell membrane increases significantly, as demonstrated by US MD
simulations. Hence, MEL will already be able to penetrate inside the cell interior at lower treatment
doses. Our results show that this synergy between PT-PBS and MEL has great potential for cancer
therapy based on MEL, as it might help to reduce the non-specific toxicity of MEL.
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